With An Uncertain Future, TherapeuticsMD Looks To New Prospects For Survival
TX-004HR received a CRL on May 5, 2017. Outcome of a Type A meeting with FDA to discuss the future course for TX-004HR is expected soon. The company is getting
(AXSM) Mcap $90 M /Cash $55 M / 5x Phase 3 programs in various indications targeting huge Markets with first results in Q3 2017 =10+ BAGGER ....GLTA !
Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .
This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL
Market-Cap: $90 Million Cash: $55 Million(cash runway into the first quarter of 2019.) Price:$3.90
Shares Out: 23.5 Million
Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
Down 3.2%? I guess NVO wasn't buying back shares today
This just got approved by fda
Do you think this thing is done selling? Showing us a buy signal now on NVO? Yo you should really check out awesome.stock.s, they seem on point with their stocks.
does this company send out 1099 or k1 form ? thanks
NVO Nonacog beta pegol $40.85 BLA filing announced May 16, 2016. PDUFA estimate May 16, 2017. Advisory Committee Meeting April 4, 2017.
Woohoo NVO beat and raise. Although, the profit forecast is still only a miserable couple of points on the plus side.
@@@@Novo Nordisk A/S (NVO) shares surged to a seven-month high Wednesday after the world's biggest maker of insulin posted stronger-than-expected first quarter earnings and boosted its full-year outlook. Novo Nordisk said sales for the three months ending in March rose 5% to Dkr28.5 billion ($4.2 billion), beating the FactSet compiled consensus of Drk27.9 billion. Operating profit for the quarter was also ahead of expectations, rising 10% to Dkr13.5 billion. The group also raised the lower portion of its full-year operating profit forecast range by around one percentage point to between -1% and +3% compared for a previous estimate of -2% to +3%.
Novo Nordisk Hits 2017 High After Q1 Profit Beat, Full-Year Guidance Boost
Novo Nordisk shares surged to a year-to-date high Wednesday after the world's biggest maker of insulin posted stronger-than-expected first quarter earnings and boosted its full-year outlook.
Novo Nordisk A/S - Reduction of the share capital
Bagsværd, Denmark, 21 April 2017 - At Novo Nordisk's Annual General Meeting on 23 March 2017, it was decided to reduce the company's B share capital from DKK 402,512,800 to DKK 392,512,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 10,000,000 divided into 50,000,000 B shares of DKK 0.20 each.
Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled nominally DKK 10,000,000 B shares. After the reduction of the share capital, the company's share capital is nominally DKK 500,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 392,512,800.
The reduction in the share capital will not affect Novo Nordisk's share repurchase programme which will continue as previously announced.
Received an alert this am about $NVO from http://thesubwaytrader.com/?s=NVO, you may want to take a look. Trading stocks day trading. Law of promotional tours: jet lag accumulates unit directionally towards maximum difficulty to perform.
The Subway Trader: Trading Stocks and Making Money
Stock alerts from the The Subway Trader. Stock trading, making money and always looking for the next big money maker.
So who is driving up NVO share price...earnings next week.
worst company ever!
Noone wants to talk about Novo Nordisk? (sad...)
Less sugar equals less diabetes.
@@@Following a long-term push to meet a shifting consumer demand for healthier products, Switzerland-based Nestlé SA (NSRGY) says that by next year, KitKat, Aeros, Lion and After Eight chocolate candies will have 10% less sugar. The world’s largest food company indicates that the 7,500 metric tonnes of sugar will be replaced with existing and non-artificial ingredients.“Nestlé is at the forefront of efforts to research and develop new technology that makes food products better for our consumers. These innovations will help us to reduce sugar in confectionery when they are combined with other, more common methods like reformulating recipes and swapping sugar for other, non-artificial ingredients,” said Fiona Kendrick, chairman of Nestlé UK and Ireland.
The food company's latest announcement reflects the trend to attract health-conscious consumers.
And now, throw in a possible acquisition to complicate execution. Quite the quagmire NVO is in. Being forced to step so far out of its comfort zone must be very unnerving to those executives who have been wearing rose colored glasses for the last couple of years.
@@@@Danish drugmaker Novo Nordisk A/S (NOVOb.CO) has approached Global Blood Therapeutics Inc (GBT.O), a U.S. biotechnology company focused on serious blood disorders, to discuss a potential acquisition, people familiar with the matter said.The approach comes as Novo Nordisk seeks to shore up declining sales from its aging diabetes franchise. With its suite of blood disease treatments under development, Global Blood Therapeutics would be a boon to Novo Nordisk's portfolio.
Exclusive: Novo Nordisk in bid for Global Blood Therapeutics - sources
Danish drugmaker Novo Nordisk A/S (NOVOb.CO) has approached Global Blood Therapeutics Inc (GBT.O), a U.S. biotechnology company focused on serious blood disorders, to discuss a potential acquisition, people familiar with the matter said.
The situation in the US continues to degrade for NVO. The Head of NA Operations has resigned.
@@@@Novo Nordisk (NOVOb.CO), the world's largest insulin maker, said on Wednesday the head of its North American operations Jakob Riis has resigned, casting doubt over its strategy in a market that accounts for more than half its sales. Riis joined the company in 1996 but was appointed to his current role only in September. The resignation comes after Novo Nordisk disappointed investors last month with a lower 2017 sales and profit growth forecast, citing price pressure and political uncertainty in the United States. Riis had previously been regarded as heir apparent to Lars Rebien Sorensen, who stepped down as long-serving CEO in September last year.
Novo Nordisk replaces head of North American operations
Based on the eps estimate for next year 2.42 in the short-term NVO does not seem to be like a good trade. Im not sure about you guys but awe-someSTOCKS has provided me with some pretty good trade ideas. I messed up executing some of them but thats on me.
Another guidedown Now NVO is forecasting ~2% revenue and ZERO profit growth in 2017 Yuk.
@@@Novo Nordisk (NVO) shares slumped after the world's largest diabetes drug maker reported disappointing fourth-quarter operating profits due to price pressure and increased competition in the U.S. Novo Nordisk also lowered its 2017 operating profit and sales growth outlook, which pushed shares down more than 5.3% by at 0920 GMT in Copenhagen to change hands at Dkr236 each and wiping out all of the gains recorded in the past three months. The company lowered its 2017 sales forecast to be in the range of a decline of 1% to a growth of 4%, and operating profit growth to be between a decline of 2% and growth of 3%, both in local currency. "2016 was a challenging year. While we met our financial guidance for the year, strong market headwinds in the USA meant that we had to revise our long-term financial target
Novo Nordisk increased adjusted operating profit by 6% in local currencies in 2016
Sales increased by 6% in local currencies and by 4% in Danish kroner to DKK 111.8 billion.
Sales of Tresiba® increased by 221% to DKK 4.1 billion (219% in Danish kroner). Sales of Victoza® increased by 12% to DKK 20.0 billion (11% in Danish kroner). Sales of Saxenda® increased by 245% to DKK 1.6 billion (243% in Danish kroner). Sales in the USA increased by 4% (4% in Danish kroner). Sales in International Operations increased by 14% (2% in Danish kroner). Sales in Region China increased by 12% (6% in Danish kroner). Operating profit was unchanged in local currencies and decreased by 2% in Danish kroner to DKK 48.4 billion. Adjusted for the non-recurring income related to the partial divestment of NNIT and the income related to out-licensing of assets for inflammatory disorders, both in 2015, operating profit in local currencies increased by 6%, in line with the most recent guidance of a '5-7% growth in local currencies' provided in October 2016. Net profit increased by 9% to DKK 37.9 billion. Diluted earnings per share increased by 11% to DKK 14.96. Adjusted for the partial divestment of NNIT, net profit and diluted earnings per share increased by 17% and 19%, respectively.
In November 2016, Novo Nordisk announced that Tresiba® demonstrated a safe cardiovascular profile and a statistically significant 40% reduced risk of severe hypoglycaemia compared to insulin glargine U100 in the DEVOTE trial.
Also in November 2016, Novo Nordisk received the FDA approval of Xultophy® 100/3.6, the once-daily combination of insulin degludec (Tresiba®) and liraglutide (Victoza®). In January 2017, Novo Nordisk received EU approval of Fiasp®, the new-generation fast-acting insulin.
On 1 January 2017, Lars Fruergaard Jørgensen replaced Lars Rebien Sørensen as president and CEO, who retired after 34 years of loyal service with the company, the last 16 years as CEO.
For 2017, reported sales growth is expected to be 1-6% measured in Danish kroner, positively impacted by currencies of 2 percentage points. Reported operating profit growth is expected to be 0-5% measured in Danish kroner, positively impacted by currencies of 2 percentage points.
At the Annual General Meeting on 23 March 2017, the Board of Directors will propose a final dividend of DKK 4.60 for 2016 per share of DKK 0.20. The expected total dividend for 2016 of DKK 7.60 per share, of which DKK 3.00 per share was paid as interim dividend in August 2016, corresponds to an increase of 19% compared to 2015. The Board of Directors furthermore intends to initiate a new 12-months share repurchase programme of up to DKK 16 billion.
Lars Fruergaard Jørgensen, president and CEO: "2016 was a challenging year. While we met our financial guidance for the year, strong market headwinds in the USA meant that we had to revise our long-term financial targets. However, 2016 was also a year in which we announced very encouraging clinical data for our key products, providing a solid foundation for future growth."